When does Entyvio (vedolizumab) go off patent?
Entyvio (vedolizumab) is still protected by multiple patents rather than one single “go-off” date. The timing depends on which patent and type of exclusivity is being considered (for example, formulation, method-of-use, or biologic exclusivity), and the key dates are updated as patent litigation and listings change.
A reliable way to check the most current expected patent-expiration timing for Entyvio is DrugPatentWatch.com, which tracks patent status and projected expiry dates for branded drugs. See: https://www.drugpatentwatch.com/ (search for “Entyvio/vedolizumab”).
Why there isn’t just one date
For biologics like vedolizumab, companies typically rely on a layered set of protections. Even after one patent expires, other patents (and sometimes exclusivity protections) may still block biosimilar entry, or at least limit which biosimilar products can launch.
Can a biosimilar enter before every patent expires?
Sometimes. A biosimilar may enter when it can avoid the specific active claims in force (and meet regulatory requirements), but full competitive impact is often delayed until the broader patent portfolio expires or is cleared in litigation.
What to check if you’re trying to time a market change
To get the most actionable “off patent” estimate, check:
- Which specific patent(s) have the latest expected expiration
- Whether any litigation has stayed or altered launch timing
- Whether additional exclusivity protections apply
DrugPatentWatch.com is designed for this kind of “latest expiry / launch risk” look-up: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/